Benjamin A. Lasky

I'll research this attorney before drafting.

Benjamin A. Lasky — Patent Litigation Practice Summary

Specialty / focus. Lasky's practice is centered on patent litigation across a wide technical range, with life sciences as the core. Kirkland's own practice description lists small-molecule pharmaceuticals and biologics (including Hatch-Waxman ANDA and BPCIA biosimilar litigation), consumer healthcare products, medical devices, software and encryption, telecommunications, optics, mining equipment, gaming devices, information storage media and digital rights management. His PTAB filings and hearing appearances confirm a heavy antibody/biologics emphasis (humanized antibody and monoclonal antibody patents), and his district court work has included glucose-sensor/continuous-monitoring technology and cardiovascular devices.

Side preference. The tracked dockets show one plaintiff-side and one defendant-side appearance — genuinely both sides rather than a one-way practice. The plaintiff-side matter is Amgen Inc. v. Amneal LLC et al., where he is listed as lead counsel for Amgen; that is consistent with his brand/innovator-pharma representation (he has also appeared for Pfizer in PTAB proceedings). The second tracked entry is a defendant-side matter at Kirkland in which he served as trial counsel. There is no indication of NPE/PAE plaintiff work; his clients are operating companies.

Firm context. He is a partner in Kirkland & Ellis LLP's New York office (601 Lexington Avenue) and a member of the firm's Intellectual Property Group. Before joining Kirkland he was an associate in the Australian IP litigation group at Freehills (now Herbert Smith Freehills), handling patents, copyright, trademarks, trade practices and advertising.

Notable cases / PTAB. His most visible PTAB work is as petitioner's counsel in the consolidated Pfizer, Inc. (and Samsung Bioepis) v. Genentech, Inc. reviews of U.S. Patent No. 6,407,213 (IPR2017-01488/-01489), where he argued the July 2018 oral hearing and the Board's November 2018 final written decisions held a substantial set of the challenged anti-HER2 antibody claims unpatentable, while upholding others. He also appears in other Pfizer IPRs (e.g., IPR2017-00731, U.S. Pat. 7,846,441; IPR2017-00804/-00805, U.S. Pat. 6,627,196) and has been admitted pro hac vice in multiple PTAB proceedings. Note that he is not a USPTO-registered patent attorney on the filings reviewed; in those IPRs registration was held by co-counsel, with Lasky appearing pro hac vice. I could not independently verify a specific outcome in the tracked Amgen v. Amneal docket or identify the caption of the second tracked matter from public search results, so no result is attributed to either. He was recognized among Lawdragon's 2025 Leaders in Global IP.

Bar / education. Admitted in New York (2006); also admitted in the S.D.N.Y., E.D.N.Y., E.D. Mich. and the Federal Circuit. University of New South Wales (LL.B., 2001; B.Sc. Genetics, 2001) and College of Law, Sydney (Grad. Dip. Legal Practice, 2002).